USA - engelska - NLM (National Library of Medicine)

sypharma pty ltd - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37) - sodium chloride 600 mg in 100 ml - sykes electrolyte solution compound sodium lactate (hartmann’s solution) is indicated as a source of water and electrolytes for all species. it is also used as an alkalinizing agent. sykes electrolyte solution compound sodium lactate (hartmann’s solution) is contraindicated in patients with a known hypersensitivity to sodium lactate; congestive heart failure or severe impairment of renal function; clinical states in which the administration of sodium and chloride is detrimental.

Irland - engelska - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - glucose (as monohydrate); magnesium chloride hexahydrate; calcium chloride dihydrate; lactic acid; sodium chloride ph.eur.; potassium chloride; sodium hydrogen carbonate; calcium; magnesium; sodium; lactate; hydrogen carbonate; chloride; potassium; glucose - solution for haemodialysis/haemofiltration - 2 millimole(s)/litre - hemofiltrates

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

delfi marketing sdn.bhd. - calcium chloride; lactic acid; sodium hydroxide; potassium chloride; sodium chloride (salt) -

USA - engelska - NLM (National Library of Medicine)

baxter healthcare corporation - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid, unspecified form (unii: 33x04xa5at) (lactic acid, unspecified form - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - calcium chloride 0.184 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. phoxillum and prismasol replacement solutions are contraindicated in patients with known hypersensitivities to these products. prismasol and phoxillum are pharmacologically inactive solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with prismasol and phoxillum solutions. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established based on published clinical data of crrt replacement solutions with compositions similar to prismasol and phoxillum used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old. the experience with prismasol and phoxillum solutions in geriatric patients has not identified novel concerns.

Malta - engelska - Medicines Authority

gambro lundia ab - magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate, lactic acid, calcium chloride, dihydrate, potassium chloride, glucose anhydrous - solution for haemofiltration - magnesium chloride hexahydrate 0.102 millimole(s)/litre ; sodium chloride 6.128 millimole(s)/litre ; sodium hydrogen carbonate 2.936 millimole(s)/litre ; lactic acid 0.27 millimole(s)/litre ; calcium chloride dihydrate 0.257 millimole(s)/litre ; potassium chloride 0.149 millimole(s)/litre ; glucose anhydrous 1.1 millimole(s)/litre - blood substitutes and perfusion solutions

Israel - engelska - Ministry of Health

teva medical marketing ltd. - calcium chloride; lactic acid as sodium; potassium chloride; sodium chloride - solution for injection - sodium chloride 6 g/l; potassium chloride 0.3 g/l; calcium chloride 0.2 g/l; lactic acid as sodium 3.1 g/l - electrolytes with carbohydrates - electrolytes with carbohydrates - as a supply of water, for administration of electrolytes or calories, or as an alkalinizing agent.

Irland - engelska - HPRA (Health Products Regulatory Authority)

bieffe medital spa - sodium chloride potassium chloride calcium chloride dihydrate lactic acid sodium hydroxide - solution for infusion - 500 millilitre

Irland - engelska - HPRA (Health Products Regulatory Authority)

bieffe medital spa - sodium chloride potassium chloride calcium chloride dihydrate lactic acid sodium hydroxide - solution for infusion - 1000 millilitre

Irland - engelska - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - potassium chloride ; sodium chloride ; glucose monohydrate - solution for infusion - 0.3/0.18/4 %w/v - electrolytes with carbohydrates

USA - engelska - NLM (National Library of Medicine)

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium phosphate, dibasic (unii: gr686lba74) (sodium cation - unii:lyr4m0nh37, phosphate i - calcium chloride 0.139 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances.they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. none pregnancy category c animal reproduction studies have not been conducted with prismasol and phoxillum solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-